Otsuka Pharmaceutical Factory released
ELNEOPA No. 1 Injection & ELNEOPA No. 2 Injection
- the world's first TPN* solution formulated with five types of trace elements-
High-calorie TPN solution containing glucose, electrolytes, amino acids, multi-vitamins and
trace elements to be launched September 28, 2009 in Japan

*TPN: Total Parenteral Nutrition

Tokyo, Japan, September 28, 2009 -- Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto,
Tokushima, Japan; President: Ichiro Otsuka) has announced the September 28, 2009 launch of
ELNEOPA No. 1 Injection and ELNEOPA No. 2 Injection, the world's first high-calorie TPN solutions
formulated with five types of trace elements. The two new ELNEOPA solutions will debut in 1000-ml
and 1500-ml formulations, with a 2000-ml formulation scheduled for introduction on November 30,
2009.

Containing a balanced complement of glucose, electrolytes, amino acids, multi-vitamins and five trace
elements (zinc, iron, copper, manganese, and iodine) required for parenteral nutrition regimens, these
new high-calorie TPN solutions make it easy to administer appropriate amounts of vital nutrients.

New ELNEOPA No. 1 and ELNEOPA No. 2 solutions are packaged in four-chamber bags, including
two divided chambers within the upper chamber, a V-chamber for vitamins and a T-chamber for trace
elements. A world's first, this innovative quad-bag kit formulation permits instantaneous one-push sterile compound preparation.

By combining glucose, electrolytes, amino acids, multi-vitamins and trace elements in a single
formulation, these new TPN solutions not only eliminate worries about forgetting to administer trace
elements and vitamins but also reduce hygiene management risks inherent in the compounding
process. Requiring no separate compounding of trace elements or vitamins, the simplified kit
formulations are suitable for parenteral nutrition management in a hospital setting or at home.

Featuring a superior gas barrier function, the newly developed bags were conceived to ensure stability
of vitamins after the compounding process. The new solutions permit administration of 2000-ml of
TPN with a single bag per day, and dosage amounts can be adjusted in 500-ml increments by different
combinations of 1000-ml and 1500-ml bags.

While nutrition management is vital for recovery from illness or surgery and to promote
self-sufficiency, reduction of the burden on healthcare professionals and caregivers is also an
increasingly vital issue. Continuing to provide information and products for appropriate nutritional
management, Otsuka Pharmaceutical Factory is committed to being the best partner of both patients
and healthcare professionals in the field of clinical nutrition.
Product Overview

Product name: ELNEOPA No. 1 Injection; ELNEOPA No. 2 Injection

Category: High-calorie TPN solution, containing glucose, electrolytes, amino acids, vitamins, and trace elements

Packaging: ELNEOPA No. 1 Injection: 1000-ml, 1500-ml, and 2000-ml* bags
ELNEOPA No. 2 Injection: 1000-ml, 1500-ml, and 2000-ml* bags

Indications: Replenishment of liquids, electrolytes, calories, amino acids, vitamins, zinc, iron, copper, manganese, and iodine by intravenous infusion for management of nutritional requirements for patients unable to obtain adequate oral or enteric nutritional support

Dosage and administration:

**TPN formulation intended as an initial solution at the initiation of central venous infusion (parenteral nutrition management) when the patient's glucose tolerance is uncertain or when glucose tolerance has deteriorated and/or as a maintenance solution when it is necessary to regulate glucose levels due to deterioration of glucose tolerance caused by stress or other factors.**

To administer, the membranes separating the upper and lower chambers and the ocher and red chambers within the upper chamber should be opened simultaneously and contents mixed well for use as an initial or maintenance solution.

The usual adult daily dosage is 2000 ml administered continuously via central vein over the course of 24 hours; dosage may be adjusted according to the patient's symptoms, age, and body weight.

**ELNEOPA No. 1 Injection**

TPN solution intended as a maintenance solution for central venous infusion (parenteral nutrition management).

To administer, the membranes separating the upper and lower chambers and the ocher and red chambers within the upper chamber should be opened simultaneously and contents mixed well for use as an initial or maintenance solution.

The usual adult daily dosage is 2000 ml administered continuously via central vein over the course of 24 hours; dosage may be adjusted according to the patient's symptoms, age, and body weight.

<NOTES ON DOSAGE AND ADMINISTRATION>

If the patient exhibits symptoms of jaundice, increased blood levels of manganese, and/or increased levels of copper or other trace elements in blood plasma, administration should be stopped and other high-calorie TPN treatment should be considered.
Storage: Store at room temperature, away from direct light.

Date of approval: March 31, 2009

Date of listing of NHI reimbursement price: September 18, 2009

Price:

<table>
<thead>
<tr>
<th></th>
<th>ELNEOPA No. 1 Injection</th>
<th>ELNEOPA No. 2 Injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000-ml bag</td>
<td>¥1,672</td>
<td>¥1,801</td>
</tr>
<tr>
<td>1500-ml bag</td>
<td>¥2,119</td>
<td></td>
</tr>
<tr>
<td>2000-ml bag*</td>
<td>¥2,565</td>
<td>¥2,779</td>
</tr>
</tbody>
</table>

Manufacture and sales: Otsuka Pharmaceutical Factory, Inc.

Sales collaboration: Otsuka Pharmaceutical Co., Ltd.

*2000-ml formulation will be released November 30, 2009

Contact:
Yoko Ishii
Otsuka Holdings Co., Ltd.
Corporate Communication Department
Tel: +81·3·6361·7411 (direct)
Fax: +81·3·6717·1409
E-mail: ishiyoy@otsuka.jp